COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

ACTRI and Pfizer Announce the Call for Pre-Proposals for Biotherapeutic and Small-Molecule Targets

Deadline for pre-proposals: Friday, November 2, 2018

UC San Diego Altman Clinical and Translational Research Institute (ACTRI) and Pfizer's Center for Therapeutic Innovation (CTI) are seeking pre-proposals from UC San Diego Health Sciences faculty interested in a drug discovery collaboration with the Pfizer CTI. Proposals are sought for biotherapeutic and small-molecule targets.

Prior to submitting a pre-proposal, investigators are encouraged to meet with Dr. Mary Faris, Senior Director, ES&I, Pfizer, to discuss their projects for suitability for the drug discovery partnership.

CTI Looks for projects geared to drug discovery efforts with the following characteristics:

  • Strong project rationale, demonstrated association between target biology and disease mechanism
  • Novel drug targets with potential to lead to differentiated drugs
  • Link between target pathway and human disease
  • Ability to address unmet medical needs
  • Feasibility: tractable target, potential for discovery/development plan

Modalities Considered

  • Large Molecules: antibodies, proteins, fusion proteins, antibody conjugates
  • Small Molecules: target classes include kinases, deubiquitinating enzymes, GPCRs, ion channels, solute transporters, and epigenetic targets

Therapeutic Areas of Interest and Targets/Pathways Focus for Fall 2018

Disease Area Focus:

  • Cancer – Select solid tumors, such as Colorectal, Breast, Lung (small cell and non-small cell), Pancreatic, Ovarian
  • Autoimmunity/Inflammation – IBD, NAFLD/NASH, Atopic Dermatology, Psoriasis
  • Metabolic - T2DM, Cachexia
  • Rare - ALS, Huntington’s, Duchene’s or Becker’s muscular dystrophy, non-malignant hematological disorders

Targets/Pathways Focus:

  • Immune Activators /Enhancers (e.g., nucleic acid sensing, TLRs, etc.)
  • DNA Damage Recognition & Repair (e.g., replication stress or repair enzymes)
  • Tissue–Resident Immune modulation ( adaptive & innate, TME, organ specific, such as skin or gut)
  • Modulation of tumor cell heterogeneity, senescence, plasticity (including drug resistance)
  • Regulation of epithelial biology (i.e. restoring barrier health/integrity)
  • Modulation of fibrosis pathways either metabolism/stress-induced, or inflammation-induced (possibly tumor-driven)
  • Regulation of antigen-specific tolerance induction and/or modulation of T regulatory cells
  • Treatments for repeat expansion diseases including Huntington’s disease, ALS/FTD and myotonic dystrophy
  • Interventions to address skeletal and cardiac muscle diseases (including Duchenne or Becker muscular dystrophies)

CTI Collaborations may include:

  • Funded project-related research
  • Hands-on partnering from dedicated Pfizer drug-development experts
  • Collaborative use of Pfizer’s science and technologies
  • Financial incentives in the form of milestone and royalty payments for successful programs
  • Flexible publishing rights
  • Involvement of CTI's Foundation alliances

Pre-proposal Submission Process

Submission entails a non-confidential 2-3 page overview of the target, mechanism, evidence for disease linkage, and the proposed therapeutic drug. At a high level, the pre-proposal should suggest how the therapeutic hypothesis could be tested in the clinic.

For Information

Please contact Mary Faris and Amrit Shahzad

Please click images below to download relevant documents

CTI Pre-proposal Template
CTI Pre-proposal Template

UCSD 2018 CT Large Small Flyer Cycle 2
UCSD 2018 CT Large Small Flyer Cycle 2